Many patients with heart dysfunction have pulmonary hypertension, more so if they have enlarged hearts or irregular ...

Gradient Denervation Technologies announced today that it received FDA breakthrough device designation for its denervation ...

The following is a summary of "Prognostic value of non-invasive right ventricle-pulmonary artery coupling in patients with ...

The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration ...

Despite the ongoing litigation, UTHR is not currently seeking any injunction against the FDA to prevent final approval of the ...

A 65-year-old woman presents to her primary care provider with a chief complaint of "feeling winded" for the last 3 weeks.

UTHR is currently not seeking any injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA. As previously announced, the FDA seta Prescription Drug User Fee ...

A combination treatment may improve survival in patients with both pulmonary hypertension and pulmonary fibrosis, a study ...

Patients suffering from long COVID may exhibit persistent inflammation in the heart and lungs for up to a year following SARS-CoV-2 infection-even when standard medical tests return normal ...

Patients suffering from long COVID may exhibit persistent inflammation in the heart and lungs for up to a year following SARS ...